Several cytokines have been suggested to play a regulatory action on the neoplastic clone of patients with B-cell chronic lymphocytic leukemia (B-CLL) by interfering in the differentiation, proliferation, or death/survival pathways. Interleukin-8 (IL-8) is a chemoattractant protein constitutively expressed at the mRNA level and released by B-CLL cells. In view of the presence of the IL-8 receptor mRNA and of specific IL-8 binding, confirmed also by Scatchard analysis using I-IL-8, the study was extended to evaluate the possible regulatory role of this cytokine on B-CLL cells. 11-8 failed to show any in vitro proliferative effect on leukemic B-CLL cells. By contrast, the propidium iodide (PI) staining of the DNA content showed that IL-8 could prolong the survival of resting B-CLL cells in 11 of 16 cases studied. In the remaining 5 cases, 90.6% k 4.39% SD of the cells after culture remained viable and IL-8 could exert a significant death protection same cells, further pointing to true autocrine and/or paracrine pathogenetic cytokine loops other than those due only to cellular interactions in the control of the disease in vivo. ' We recently described the constitutive production and release of biologically active IL-8 by B-CLL cells and the increased levels detected in the serum of the patients." IL-8 is an inflammatory cytokine with chemotactic properties towards neutrophils, T cells, and eosinophils," but an IL-8-related function on B lymphocytes has never been reported.
B characterized by the accumulation in the peripheral blood of slowly dividing monoclonal CD5+ B lymphocytes. ' The reasons for this accumulation process, typical of this disorder, are still largely unclear. A better understanding of the underlying mechanisms would open new strategies towards a more physiologic management of the disease. Over the last few years, several cytokines have been shown to interfere in the in vitro process of cell accumulation. At concentrations of 0.5 to 10 ng/mL, interleukin-4 (IL-4) inhibits the spontaneous and induced apoptosis of B-CLL interferon a (IFNa; 1,000 U/mL) increases the survival of B-CLL cells and reduces the spontaneous DNA fragmentation of the leukemic cells4; 100 U/mL of IFNy promotes the survival of B-CLL cells5; and IL-10 (100 ng/mL) specifically induces apoptotic cell death of B-CLL cells6 The spontaneous death of B-CLL cells observed in vitro in a proportion of contrasts with the long survival in vivo of the same cells, further pointing to true autocrine and/or paracrine pathogenetic cytokine loops other than those due only to cellular interactions in the control of the disease in vivo. ' We recently described the constitutive production and release of biologically active IL-8 by B-CLL cells and the increased levels detected in the serum of the patients." IL-8 is an inflammatory cytokine with chemotactic properties towards neutrophils, T cells, and eosinophils," but an IL-8-related function on B lymphocytes has never been reported.
In the present study, we further investigated the role of IL-8 in B-CLL. Evidence is provided in support of the possibility that IL-8 may be involved in an autocrine manner in the abnormal accumulation of the neoplastic clone characteristic of this lymphoproliferative disorder.
MATERIALS AND METHODS
B-CLL cell purtjication. Enriched B-CLL cells were obtained after a Lymphoprep (Nycomed AS, Oslo, Norway) gradient separation of mononuclear cells and depletion of monocytes by adherence to plastic for 60 minutes at 37°C. T lymphocytes were removed by rosette formation with sheep red blood cells (E-rosettes) and repeated Lymphoprep fractionations. After purification, the samples to be tested were controlled for viability and analyzed with selected monoclonal antibodies (MoAbs) by flow cytometry using a FACSCAN (Becton Dickinson, Mountain View, CA); they contained greater than 98% CD5/CD19 double-positive leukemic cells, less than 1% CD14+ monocytic cells, and less than 1% CD3' T cells. As previously described," in selected experiments, CD3 and CD14 "As amplifications were also used to analyze the possible contamination of T cells and monocytes, respectively.
Purified B-CLL cells were cultured for 2 to 14 days at a concentration of 2 X 106/mL in RF'MI 1640 medium Binding experiments were performed by using lZ5I-IL-8 (specific activity, 2,000 Ci/mmol) purchased from Amersham (Buckinghamshire, UK). Cells used for binding experiments were resuspended in a buffer (binding medium) consisting of RPMI 1640 medium containing 20 mmoVL HEPES (pH 7.2), 2% bovine serum albumin (BSA), and 0.02% sodium azide to inhibit the internalization of the iodinated ligand by the cells. A total of 1 X IO6 cells in 400 pL of binding medium containing various concentrations of Iz5I-IL-8 was incubated at 23°C for 2 hours (in preliminary experiments, binding at 23°C required 2 hours to reach equilibrium). After incubation, the cells were resuspended and carefully transferred onto 800 pL of precooled FBS and subsequently separated from the medium by centrifugation at 10,000 rpm in a microfuge. Medium and serum were aspirated and the cell sediment was sliced off with a razor blade to measure radioactivity with a gamma counter (Packard, Downers Grove, IL) with a counting efficiency of 70% for Iz5I. Duplicate determinations were performed for each IL-8 concentration. Specific binding was determined as the amount of binding blocked by competition with a 100 fold excess of unlabeled IL-8. Unspecific binding was defined as the amount of binding not displaced in the presence of excess cold ligand.
Receptor numbers and binding affinities were estimated by Scatchard analysis" using the Enzfitter computer program (Elsevier Biosoft, Cambridge, UK).
Total cellular RNA was extracted according to the method of Chomczynski and SacchiI3 using the RNAzol solution (Cinna/Biotec, Houston, TX). RNAs were then treated for 30 minutes at 37°C with 1 U/pg of RQl RNase-free DNase (Promega, Madison, WI) in 40 mmoVL Tris-HC1, pH 7.9, 10 mmol/L NaCl, 6 mmoVL MgCI2, and 0.1 mmoVL CaCI,. cDNAs were prepared by reverse transcription at 42°C for 30 minutes in a 50-pL reaction mixture containing 2 pg of total RNA, 0.5 mg oligo-dT, 1 mmol/L dNTPs (2'-deoxynucleo- 
Reverse transcriptase-polymerase chain reaction (RT-PCR).
ent primers tested. Fifteen microliters of PCR product was electrophoresed in a 2% agarose gel in Trishric-acid/EDTA buffer. Gels were stained with ethidium bromide and photographed. Specific primers for high-affinity IG8 receptor mRNA (5'-1TCACTGGC-were designed on the basis of published sequences.15 Bcl-2 mRNA primer sequences (5'-TTCGCCGAGATGTCCAGCC; 3'-TCACIT-GTGGCCCAGATAGG) were kindly provided by A. Alfarano and E. Gottardi (Dipartimento di Scienze Biomediche e Oncologia Umana, Torino, Italy). IL-8 (5'-ATGACTTCCAAGGCTGGCCGT-GGCT; 3'-TCTCAGCCCTCITCAAAAACITCTC) and &-microglobulin (P2-M, 5'-CTCGCGCTACTCTCTC"TTCTGG; 3'-GCT-TACATGTCTCGATCCCACTTAA) specific mRNA primers were purchased from Clontech (Palo Alto, CA). All reagents for cDNA synthesis and PCR are from Promega.
For intracellular detection of bcl-2 protein, l X 10' cells were fixed in 2% paraformaldehyde and pemeabilized after 10 minutes of incubation at 4°C in saponine (1 mg/mL in PBS) before staining with an FITC-conjugated antihuman bcl-2 IgG, MoAb (DAKO, Glostrup, Denmark) or with a mouse IgG, FITC-conjugated MoAb.
A total of 2 X lo5 cells were cultured at 37°C in flat-bottom microplate wells in 0.2 mL of RPMI 1640 medium containing 10% FBS and supplemented with nothing or with 5 or 50 ng/mL of IL-8. After 2 days of incubation at 37"C, cultures were pulsed for 18 hours with 1 mCi/well of 'H-TdR (specific activity, 2 Ci/mmol; New England Nuclear, Dreieich, Germany) and the incorporated radioactivity was determined using a liquid scintillation counter.
A total of 1 X IO6 cultured cells were centrifuged and cell pellets were gently resuspended in 1.5 mL hypotonic fluorochrome solution (PI) at 50 pg/mL in 0.1% sodium citrate plus 0.1% Triton X-100 (Sigma Chemical Co). The tubes were placed at 4°C in the dark overnight. The PI fluorescence of individual nuclei was measured using a FACSCAN flow cytometer.I6
The paired t-test was used to analyze the statistical significance of the experimental results.
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RES U LTS
In agreement with our previous report," all 9 B-CLL samples tested constitutively expressed the mRNA for IL-8 and released between 0.3 and 6.5 ng/mL (3.4% 2 2.3% SD) of IL-8.
The presence of the IL-8 receptor mRNA was investigated in 9 unstimulated B-CLL samples after T and monocyte depletion. Using RT-PCR analysis, the 439-bp IL-8 receptor-specific fragment was detected in 7 cases (5 representative samples are shown in Fig 1) . The 2 negative results were derived from stocked RNA samples; this prevented further IL-8 binding studies to be performed on these cases (see below). B-CLL cells maintained a stable mRNA expression of the IL-8 receptor after 2 to 3 days of culture.
To sustain the mRNA RT-PCR data, we searched for the presence of the surface IL-8 receptor on B-CLL cells. The cytofluorimetric detection of IL-8-PE bound to B-CLL cases was positive in all 10 enriched B-CLL samples tested (a representative case is shown in Fig 2) and the presence of the IL-8 receptor remained unchanged over a 6-day culture period. IL-8-PE binding to B-CLL membranes was inhibited after coincubation of the cells with 1 pg of recombinant unlabeled IL-8 (Fig 2) or apoptotic cells formed different populations with lower amounts of DNA. In 11 of the 16 (69%) cases studied, an increase in the percentage of living cells after IL-8 treatment was observed (Fig 4A) . This effect became apparent at the 5 ng/mL IL-8 dose (P = .001) and increased further in the presence of 50 ng/mL (P = .OOOl). In all but 2 cases, higher concentrations of IL-8 (100 to 500 ng/mL) induced a greater proportion of dying cells than in the control. In the majority of cases (n = 6), the effect was evident after 2 days of For culture; in the other cases, the best response was observed at 7 days (n = 5). The simultaneous presence of a neutralizing anti-IL-8 MoAb abolished and reversed the IL-&in-duced prolonging survival effect (see below).
In the remaining 5 of 16 cases, very high spontaneous survival percentages (90.60% 2 4.39% SD) were recorded after 2 days of incubation and this prevented the addition of exogenous IL-8 to induce a further death protection effect (Fig 4B) . However, treatment for 2 days with m o m of HC reduced in these 5 cases the percentage of residual living cells to 55% 5 13.8% SD, and again, under these conditions, the addition of 5 ng/mL of E-8 induced a significant rescue of dying cells (P = .05; Fig 4C) . Figure 5 illustrates the cytofluorimetric profile of the E-%mediated rescue from cell death in 2 representative untreated (Fig 5A) and HCtreated (Fig 5B) B-CLL cases.
A complete or partial B-CLL spontaneous death abrogation was observed after culture of B-CLL cells in the presence of E-4 (10 ng/mL) or IFNcr (500 U), respectively (data not shown). However, the IL-4-and IFNa-induced B-CLL survival did not synergize with IL-8 death abrogation.
IL-8-mediated regulation of bcl-2 mRNA expression in B-CLL cells. Constitutive mRNA expression of bcl-2 was detected by RT-FTR in the 7 B-CLL samples examined.
When the cells were incubated with 5 ng/mL of IL-8 for 2 days, in 5 of the 7 samples analyzed an increase of the 
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FRANCIA DI CELLE ET AL specific bcl-2 signal was recorded compared with untreated cells, whereas the control P2-M amplifications of the same cDNAs showed a constant signal (3 representative cases are shown in Fig 6) . In 5 cases, the cells were incubated with HC. This produced a downmodulation in the expression of bcl-2. Again, and to a further extent compared with untreated cells, bcl-2 mRNA was recovered after IL-8 treatment (Fig  6) . In all but one case, the best effect was observed with 5 ng/mL of 1L-8, and higher concentrations of IL-8 (SO and 500 ng/mL) did not increase the bcl-2 mRNA expression compared with the basal level. bcl-2 protein levels were determined in permeabilized B-CLL cells by flow cytometry in IO cases. All cases constitutively expressed bcl-2 protein at a high level ( b~1 -2~'~~) and in a unimodal fashion. After 12 days of culture, 5 cases maintained the starting expression of bcl-2, and, under these conditions, IL-8 could induce no regulatory effect. In the other cases, a bimodal espression of bcl-2 protein was observed during the time course due to the proportion of cells (44.4% 5 17.4% SD) that expressed low levels of bcl-2 (bcl-2'""). In these latter cases, the addition of 5 ng/mL of IL-8 to the cultures resulted in a statistically significant (P = .01) augmentation of I~c l -2~'~~ expression, with a concomitant decrease of bcl-2'"" expression. In these 5 cases, the overall mean percentage of b~l -2~'~' ' ' expression increased to 60.4% 
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CLL was investigated. Leukemic cells from I O B-CLL cases were cultured in the presence of a neutralizing antihuman IL-8 polyclonal rabbit antiserum. Under these culture conditions, the PI evaluation of the number of living cells showed an overall 30% reduction in the number of living cells (Table  I , P = .003). By contrast, the preimmune rabbit serum used at the same dilutions used for the anti-IL-8 antiserum maintained or increased the number of untreated living cells. B-CLL cells (6 cases) were also cultured in the presence of an antihuman IL-8 MoAb; again, a statistically significant (P I -334-bp = .01) decrease in the percentage of living cells (25% of inhibition) was observed. whereas the control MoAb exerted no effect ( Table I) . The anti-IL-8 antiserum displayed its neutralizing action within 7 days of culture, whereas the anti-IL-8 MoAb required a more prolonged culture time (up to 14 days) to exert its inhibitory effect. Coincubation of 7 B-CLL samples with either the polyclonal antiserum or the monoclonal anti-1L-8 antibody and 5 ng/mL of IL-8 contrasted, although not completely, the death induction effect mediated by IL-8 neutralization (62.9% ? 23% SD of living cells in the control cultures v 44.4% ? 22.3% SD in the presence of the anti-IL-8 antibody 1' 53.2% 2 16% SD in the presence of the anti-IL-8 antibody plus IL-8). The addition of SO ng/mL did not increase further B-CLL survival.
A possible nonspecific effect of the antibodies was ruled out by incubating the Nalm-6 pre-B-cell line with the same reagents; under these conditions, no modification in cell survival was observed. It should be noted that this cell line does not express the IL-8 mRNA and does not release IL-8. We also excluded an antibody-mediated lysis directed against cell surface receptor bound IL-8, because HL60 cells, which bind IL-8, did not modify their living features after culture for up to 14 days in the presence of anti-lL-8. for the protective effect; at doses greater than 50 ng/mL, IL-8 exerts an opposite action. This may be due to a saturation of the receptors and is in agreement with previous studies with other chemotactic agents, including IL-8.22 Overall, the 5 ng/mL dose of IL-8 appears to be the most effective. This is also confirmed by the mRNA induction experiments and by the functional studies on B-CLL cells. In this respect, it is worth noting that the 5 ng/mL dose is in the range of IL-8 levels constitutively released by B-CLL cells" (present study). It appears, therefore, that the levels of IL-8 released physiologically by the leukemic cells are potentially sufficient to trigger in vivo the survival protective effect hereby documented in vitro.
Previous reports have suggested that the in vitro cytokinemediated prolonging survival effect was due to a rescue from spontaneous apoptotic death of B-CLL cells.'~' In our experiments, we could not reach the same interpretation because neither a consistent spontaneous DNA ladder (indicative of DNA fragmentation) nor a clear morphology with apoptotic bodies could be documented on primary untreated B-CLL-cultured cells. Also, the PI profile rarely showed a hypodiploid peak of DNA, indicative of a homogeneous apoptotic population, but rather a profile representative of asynchronous populations at different levels of death. Only when the cells were treated with HC was a simultaneous programmed cell death induced in a high proportion of cells,23 and, under this condition, a PI-stained apoptotic peak was observed (Fig 5B) .
After treatment with IL-8, an upregulation in the mRNA expression of bcl-2 by B-CLL cells was documented. The IL-&mediated bcl-2 upregulation was even greater on B-CLL cells pretreated with HC and in which the cytolytic action of HC had induced a downmodulation of bcl-2. These data have been corroborated by the observation of an upregulation of intracellular bcl-2 protein mediated by IL-8; this effect consists of an upmodulation of the b~1 -2~'~~ expression when B-CLL cells express bcl-2 protein in a bimodal fashion. It has, in fact, been reported that B-CLL cells constitutively express high levels of b~l -2~~
and that, during spontaneous or induced (by IL-10 or HC) apoptosis, a downmodulation of bcl-2 expression occurs that is shown by the progressive appearance of an expanded peak of bc12'"" expression documented by a cytofluorimetric intermediate bimodal profile6 (personal unpublished data). Overexpression of the proto-oncogene bcl-2 has been associated with the survival and with the prevention of the physiologic program of cell death by B cells.25 Thus, the evidence of an upregulation of bcl-2 induced in B-CLL cells by physiologic doses of IL-8 further points to the role played by this cytokine in the accumulation process characteristic of this disorder.
The final purpose of this study was to verify a possible autocrine regulation of the neoplastic clone through IL-8 production. The first observation in favor of this possibility is the demonstration of the IL-8 mRNA upmodulation after exposure to IL-8. The second and more suggestive finding is the death-induced effect exerted on B-CLL cells following endogenous IL-8 neutralization following incubation in the presence of both polyclonal and monoclonal anti-IL-8 antibodies. IL-8 neutralization on cells that produce and bind IL-8 (HL60) or, conversely, that neither release, nor express, nor bind IL-8 (Nalm-6) exerted no effect. These findings support the hypothesis that, in B-CLL, the neoplastic clone contributes to its maintenance by using self-produced IL-8.
In conclusion, our analysis points to a functional role of IL-8 in B-CLL. This consists of a prolonging survival effect on spontaneous or induced dying cells mediated by physiologic doses of IL-8. This protective effect is exerted through a bcl-2-dependent pathway and appears to occur via an autocrine loop. A reduction in the number of living B-CLL cells is necessary to induce and recognize the IL-8 promoting survival effect, both in terms of the percentage of living cells and of bcl-2 upregulation. This offers an explanation for the individual behavior heterogeneity observed and suggests that mediators other than IL-8 are likely to be involved in regulating the survival mechanisms in B-CLL.
This study adds to the recent observation of a cell death protection induced in B-CLL cells by IL-4?3 IFNa? and IFNy.' However, these cytokines are usually not produced constitutively and are not expressed (except for IFNy, which has been detected at the mRNA level after in situ hybridization5) by the neoplastic clone, and their most likely paracrine action occurs at nonphysiologic doses. IL-8, which does not synergize with these molecules, is at the moment the best candidate for an autocrine cytokine prolonging survival effect on B-CLL cells. These findings extend our knowledge on the biologic properties of the leukemic growth in B-CLL and open the prospect of new therapeutic strategies aimed at interfering in the survival control of the neoplastic clone in vivo. Finally, the evidence of a functional role of IL-8 different from the known chemotactic activity and the characterization of a new potential cell target for IL-8 indi-
